Medication Management News
-
Caresyntax Announces Strategic Collaboration with AAICO to Expand AI-based Solutions In Healthcare
Caresyntax has entered into a strategic collaboration with The Applied AI Company (AAICO), a leading AI technology company, to distribute novel software and artificial intelligence solutions throughout the UAE, US, and Europe. With this strategic engagement, the companies will combine their healthcare datasets and delivery resources to offer bundled software and services solutions to healthcare ...
By Caresyntax
-
Tris Pharma Partners with Perigon Pharmacy 360 to Enhance Access to DYANAVEL® XR Tablets for the Treatment of Attention Deficit Hyperactivity Disorder
Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, today announced a new partnership with Perigon Pharmacy 360, a full-service, specialty digital pharmacy, to enhance accessibility, affordability and adherence for patients treating symptoms of ADHD with Tris’ ...
-
Alfa Chemistry Unveils Its Latest Offering of Bioactive Molecules for Scientific Breakthroughs
The US-based chemical supplier Alfa Chemistry recently announced the availability of a range of bioactive molecules for scientific research, including activators, agonists, antagonists, and inhibitors. Bioactive molecules are compounds that can interact with biological systems, such as proteins, enzymes, and the human body, and produce a physiological response. They play a crucial role in the ...
-
The Importance of Optimal Medical Therapy (OMT) and Collaborative Care
The HFSA Optimal Medical Therapy in Heart Failure (OMT-HF) program can help your patients achieve their best outcomes. An estimated 6.5 million Americans have heart failure (HF). This year alone another 960,000 will likely be diagnosed with this condition. Chances are several of your patients are in this group. Are they receiving the optimal medical therapy (OMT), that helps them achieve ...
-
Alfa Chemistry Combines the Power of Computational Chemistry for Multiple Medical Applications
Computational chemistry, a branch of chemistry that applies computer simulation to assist in solving chemical problems, is a heated topic in the modern scientific community. Possessing a powerful team of experts in chemistry, biology, mathematics, crystallography, and pharmacology, Alfa Chemistry focuses on combining the power of computational chemistry with a variety of research focuses on ...
-
Antengene Announces NDA Submission for XPOVIO in Macau,China, Malaysia and Thailand for Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-cell Lymphoma
Shanghai and Hong Kong, PRC, December 23, 2022 — Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has submitted New Drug Applications ...
-
Alfa Chemistry Enriches API Supply by Adding Lenalidomide, Parecoxib Sodium, and Rivaroxaban
As one of the leading chemical manufacturers and suppliers globally, Alfa Chemistry is well-prepared to provide a number of active pharmaceutical ingredients (APIs), such as donepezil and dexmedetomidine hydrochloride, for customers worldwide ranging from lab to commercial scale. Earlier this month, the company announced that three other APIs had been introduced for its global customers as well, ...
-
Tris Pharma Reports Positive Topline Data from Clinical Study of Investigational Pain Therapy Cebranopadol Showing Significantly Less Potential for Abuse Versus Tramadol and Oxycodone
Study evaluating human abuse potential demonstrates that the likeability of cebranopadol administered orally in nondependent recreational opioid users was significantly less as compared to immediate release (IR) formulations of either tramadol or oxycodone, suggesting a lower potential for abuse versus traditional C-II and C-IV opioids A first-in-class investigational analgesic uniquely ...
-
Pulmonx Receives Japanese MHLW Approval of Zephyr Endobronchial Valve for the Treatment of Severe COPD/Emphysema
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the Zephyr® Endobronchial Valve for treating severe COPD/emphysema patients following a positive recommendation by Pharmaceuticals and Medical Devices Agency (PMDA). ...
-
Ardent Health Services and BioIntelliSense Launch State-of-the-Art Continuous Inpatient Monitoring Initiative to Advance Care and Optimize Workflow
Clinicians at Ardent’s BSA Hospital in Amarillo, Texas, began using the BioButton wearable device and BioCloud analytics engine in September to automate the collection of inpatient vital signs in general care units and increase both patient and clinician satisfaction. With plans for expansion across Ardent’s 30 hospitals, the program also leverages BioIntelliSense’s FDA-cleared ...
-
Pulmonx to Present at the 34th Annual Piper Sandler Healthcare Conference
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference in New York on Wednesday, November 30, 2022, at 11:30 AM PT / 2:30 PM ET. A live and archived webcast of the presentation will be available ...
-
Pulmonx to Participate at Upcoming Investor Conferences
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in two upcoming investor conferences in New York. Pulmonx management is scheduled to participate in a fireside chat at the Stifel Healthcare Conference on Wednesday, November 16, 2022, at 8:00AM ET. Interested ...
-
CD Bioparticles Introduces Hydrophilic Coatings for Medical Applications
CD Bioparticles, a leading manufacturer and supplier of various drug delivery products and services, recently introduced hydrophilic coatings and related services for medical applications, which can be used within interventional medical devices of the cardiovascular, circulatory, nervous, urinary, and vascular system. Functional medical coatings are a class of interface materials applied to the ...
-
Lattice Medical announces the closing of a €8 million Series A financing round
LATTICE MEDICAL, announces the closing of a second round of financing of 8 million euros. This round was led by the historical funds Finovam Gestion, Nord France Amorçage and WiSEED alongside the Captech Santé fund. The European Commission, via its EIC Fund, and Santelys are co-investing. The financing round is completed by non-dilutive financing, in the form of a grant and debt ...
-
Alnylam Presents Additional Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Meeting
– New Data Further Support Potential for Patisiran to be an Effective Treatment for Cardiomyopathy of ATTR Amyloidosis – – Data from Exploratory Endpoints, Including Cardiac Biomarkers and Imaging, Suggest Favorable Impact of Patisiran on Measures of Cardiac Stress, Injury, Structure, and Function at Month 12 – – Treatment with Patisiran Demonstrated Generally ...
-
Terumo India Signs a New Strategic Commercial Distribution Partnership with Sensible Medical Innovations
Introduces medical radar monitoring and imaging technology (ReDS™) to Indian patients for the first time Addresses an unmet medical need for over 8 million patients across the country Terumo India, the Indian arm of Terumo Corporation (TSE: 4543), a global leader in medical technology, today announced that it has signed a partnership with Sensible Medical Innovations, the market ...
-
Sensible Medical ReDS Lung Fluid Monitor to Help COVID-19 Patients in Italy, US and Other Countries
Hospitals treating COVID-19 patients are looking to use the radar-based technology, previously used in heart-failure patients, to monitor lungs of coronavirus patients. Sensible Medical has recently received urgent requests from hospitals around the world for its ReDS monitors systems to improve monitoring, treatment and resource use for COVID-19 patients. The company has already responded to ...
-
Flowonix Medical Inc. And Cerebral Therapeutics Announce World-First Clinical Trial Delivering Medication Directly Into The Brain For Patients With Refractory Epilepsy
Flowonix Medical Inc. of New Jersey, and Colorado-based Cerebral Therapeutics, announced today the first patients implanted with the Prometra II Programmable Infusion System in the Australian Direct Drug Administration for Refractory Epilepsy (ADDRESS) clinical trial at St. Vincent's Hospital, Melbourne, Australia. The jointly developed therapy features a micro-infusion device that tightly ...
-
Cardiac telerehabilitation system implemented in Przemysl, southeast of Poland
In times of pandemic, cardiac rehabilitation centres search for solutions which allow them to continue remote rehabilitation, while making it possible to maintain constant contact with the patient. This solution must provide possibility to assess the patient's condition before training, set training parameters adjusted to individual needs and must ensure easy access to records from rehabilitation ...
By Pro-PLUS SA
-
Lattice Medical announces the success of the first breast reconstruction operation with the Mattisse implant
After the entry into clinical phase announced in early July 2022, LATTICE MEDICAL, announces the success of the first breast reconstruction operation with the MATTISSE implant. The operation took place on July 12 at the Institute of Clinical Oncology, Tbilisi, Georgia. It was conducted by Pr Gia Nemsdaze and his team, and in the presence of the co-founders of Lattice Medical, Pr. Pierre ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you